Key Highlights
- Third-quarter Revenue grew 34.1% to USD 794.0 million from USD 592.2 million in the same quarter of 2025, according to the company release dated November 5, 2026.
- The 2026 revenue outlook was raised to USD 3.005 billion to USD 3.035 billion from USD 2.850 billion to USD 2.910 billion, a USD 140 million lift at the midpoint.
- The net loss narrowed to USD 59.9 million, or USD 0.42 per share, from USD 87.5 million, or USD 0.64 per share, a year earlier.
- Shares were down 16.15% after hours on Thursday per market data, as a Leadership change was reported alongside the results.
Raised Outlook Meets an After-Hours Sell-Off
Natera (NASDAQ:NTRA) published third-quarter results on November 5, 2026, with revenue of USD 794.0 million, up 34.1%. Market data showed the stock down 16.15% in after-hours trading on Thursday, a move that can narrow or widen before the next regular session. The company also lifted its full-year revenue range by USD 140 million at the midpoint, to USD 3.005 billion to USD 3.035 billion. That is a sizable increase, so the reaction needs another explanation than the numbers alone, and the leadership announcement is the leading candidate. The new range implies a full-year midpoint of USD 3.02 billion (calculated), up from USD 2.88 billion before, so the company expects to beat its earlier plan.
The Reported CEO Change Is the Open Question
Market data said Solomon Moshkevich was named chief executive, replacing Steve Chapman. The Earnings release itself did not mention a leadership change, and a company filing confirming it could not be located during research, so the item is described as reported and unconfirmed. Natera sells blood tests that read cell-free DNA, covering prenatal screening, transplant monitoring and cancer recurrence detection. Mr. Chapman has led the company for several years, and investors often react sharply when a chief executive leaves during strong growth. The reasons for any change, and its timing, are not stated in the material reviewed. Chief executive transitions at fast-growing healthcare firms can raise questions about strategy, execution and succession planning, which markets price immediately.
Narrowing Losses and the Risks Ahead
Net loss fell to USD 59.9 million from USD 87.5 million, a reduction of about 32% (calculated), while loss per share improved to USD 0.42 from USD 0.64. Higher test volumes typically spread fixed laboratory and sales costs over more tests, which helps margins. Risks include the leadership transition, reimbursement decisions, competition in cancer monitoring and the possibility that an after-hours move reverses. Investors will look for a clear 8-K, the Earnings Call commentary and details on whether the strategy changes under new leadership. Revenue of USD 794.0 million exceeded the year-earlier USD 592.2 million by USD 201.8 million (calculated).
Where Things Stand
Natera (NASDAQ:NTRA) fell about 16% after hours most likely because the reported change at the top overshadowed a quarter that grew revenue 34.1% and lifted full-year guidance. That explanation is an inference, since the company release does not discuss the move. Fundamentals look strong, with narrower losses and a higher outlook, while governance uncertainty is the new variable. The next markers are a formal filing on leadership, the first regular-session reaction on Friday and the fourth-quarter report. After-hours Volume is thin, so quoted moves can reverse.






Please wait processing your request...